利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.013 秒)

    MACHINE LEARNING
    12.
    发明公开
    MACHINE LEARNING 审中-公开
    MASCHINENLERNEN

    公开(公告)号：EP2087461A2

    公开(公告)日：2009-08-12

    申请号：EP07824295.5

    申请日：2007-10-23

    申请人： THE UNIVERSITY OF LANCASTER

    发明人： ANGELOV, Plamen

    IPC分类号： G06N5/02

    CPC分类号： G06N99/005 ,  G06K9/6226 ,  G06N5/025 ,  G06N7/023

    摘要： Computer implemented machine learning methods are described. A co-operative learning method involves a first rule based system and a second rule based system. A rule base is generated from input data and recursion data is used to recursively update the rule base as a result of newly received input data. Rule data defining at least one rule and associated data are sent to the second system which determines whether to update its rule base using the transmitted rule data, and if so the recursion data is used to recursively determine the updated rules for its rule base. A father machine learning method for a rule based system, involves receiving time series data, determining whether the data increases or decreases the spatial density for previously existing rules, and if so then creating a new cluster and associated rule, otherwise a new cluster is not created.

    DEVICE FOR CONCENTRATING TRACE COMPONENTS IN A LIQUID
    15.
    发明公开
    DEVICE FOR CONCENTRATING TRACE COMPONENTS IN A LIQUID 失效
    设备技术微量成分在流体中的富集

    公开(公告)号：EP0713576A1

    公开(公告)日：1996-05-29

    申请号：EP94923779.0

    申请日：1994-08-12

    申请人： University of Lancaster

    发明人： DAVISON, William

    IPC分类号： G01N1 ,  G01N30 ,  G01N33

    CPC分类号： G01N30/00 ,  G01N1/34 ,  G01N1/405 ,  G01N33/1886 ,  G01N2001/4011 ,  G01N2001/4016

    摘要： A probe device for use in measuring trace quantities of a component in a liquid environment comprises: (i) a membrane (2) which is permeable to the component; and (ii) a layer of a material (4) capable of binding the component and arranged to receive material which has permeated through the membrane (2) from a face (6) thereof juxtaposed to the fluid environment. The membrane (2) may for example be a polyacrylamide gel and the material (4) an ion exchange resin. The device may be used, for example, for determining quantities of trace metals in an aqueous environment.

    Compounds and pharmaceutical preparations having calcium - regulatory activity
    16.
    发明公开
    Compounds and pharmaceutical preparations having calcium - regulatory activity 失效
    Verbindungen und pharmazeutische Zusammensetzungen mit kalziumregulierenderAktivität。

    公开(公告)号：EP0240257A2

    公开(公告)日：1987-10-07

    申请号：EP87302644.7

    申请日：1987-03-26

    申请人： University of Lancaster

    发明人： Hetherington, Alistair MacCulloch ,  Huddart, Henry ,  Mansfield, Terence Arthur ,  Langton, Philip David

    IPC分类号： A61K31/19 ,  A61K31/275 ,  A61K31/215 ,  A61K31/335 ,  A61K31/12 ,  A61K31/16 ,  A61K31/34 ,  A61K31/40 ,  A61K31/405 ,  A61K31/365 ,  A61K31/52

    CPC分类号： A61K31/275 ,  A61K31/12 ,  A61K31/16 ,  A61K31/19 ,  A61K31/215 ,  A61K31/335 ,  A61K31/34 ,  A61K31/365 ,  A61K31/40 ,  A61K31/405 ,  A61K31/52

    摘要： Pharmaceutical compositions useful in regulating calcium transport across cellular membranes in man and ani­mals are disclosed. The compositions contain plant growth regulators such as abscisic acid and its derivatives. In particular, the compositions contain a compound of the for­mula:
    or
    R₁ - Y - R₂
    wherein R₁ is an alkyl of up to seven carbons or a saturated or unsaturated six membered carbon ring, which may be sub­stituted; R₂ is a cyano group, a thio or hydroxy lower alkyl group or a group containing a carbonyl, most commonly a carboxyl group; R₃ is hydrogen or lower alkyl; R₄ is hydro­gen, lower alkyl or halide; R₅ is hydrogen or hydroxy; R₆ is hydrogen, carboxy or carboxy lower alkyl, or R₅ and R₆ form a bond between the carbons to which they are attached or with the carbons to which they are attached form a carbon ring; or R₂ and R₆ together with the carbon to which they are bonded form a heterocyclic ring; n is 0 or 1, with the proviso that when n is 0, R₂ is an acyl group; X is -CH₂-, -­CH=CH-, -CH₂-CH₂-, -CH₂-NH-, -CH₂-O-, -CH₂-S- or -NH-CO-; and Y is a carbocyclic group bonded to R₁ and R₂ through a single carbon. The compositions are formulated for oral, parenteral or other form of administration in dosages neces­sary to effect the desired change in calcium flux. Daily doses of 0.01 to 200 mg/kg in one or more doses are contem­plated. Dosage units may be formulated with any pharma­ceutically acceptable carrier which is compatible with the active ingredient.

    摘要翻译： 公开了可用于调节人和动物中跨细胞膜的钙转运的药物组合物。 组合物含有植物生长调节剂如脱落酸及其衍生物。 特别地，组合物含有下式的化合物：其中R 1为至多7个碳原子的烷基或可被取代的饱和或不饱和六元碳环; R2是氰基，硫代或羟基低级烷基或含有羰基的基团，最常见的是羧基; R3是氢或低级烷基; R4是氢，低级烷基或卤素; R5是氢或羟基; R 6是氢，羧基或羧基低级烷基，或者R 5和R 6在它们所连接的碳之间或与它们相连的碳形成碳环时形成一个键; 或R 2和R 6与它们所键合的碳一起形成杂环; n为0或1，条件是当n为0时，R2为酰基; X是-CH 2 - ， - CH = CH - ， - CH 2 -CH 2 - ， - CH 2 -NH-，-CH 2 -O-，-CH 2 -S-或-NH-CO-; Y是通过单个碳键合到R1和R2上的碳环基团。 将组合物配制成用于口服，肠胃外或其它形式的给药，其剂量必须达到理想的钙通量变化。 考虑以一个或多个剂量每天0.01至200mg的剂量。 剂量单位可以与任何与活性成分相容的药学上可接受的载体配制。